Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

Chemoimmunotherapy (CIT) and targeted therapy with single‐agent ibrutinib are both recommended first‐line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE‐2 (PCYC‐1115/1116) study conducted in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Robak, Tadeusz, Burger, Jan A., Tedeschi, Alessandra, Barr, Paul M., Owen, Carolyn, Bairey, Osnat, Hillmen, Peter, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven E., Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A., Moreno, Carol, Gill, Devinder S., Flinn, Ian W., Gribben, John G., Mokatrin, Ahmad, Cheng, Mei, Styles, Lori, James, Danelle F., Kipps, Thomas J., Ghia, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2018
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221114/
https://ncbi.nlm.nih.gov/pubmed/30129285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25259
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky